Back to Search

A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

  • Protocol Number: 201610088
  • Principal Investigator: Cashen, Amanda
  • Cancer Types: Gene & Cellular Immunotherapy, Leukemia, Myeloma, and Hematologic

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from <10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (>60% any grades or >30% grade III/IV or >= 50% severe cGVHD) or engraftment failure rates (>=15%).

Protocol Interventions

Graft cell infusion, Tacrolimus, Mycophenolate mofetil, G-CSF, CIML NK cell infusion, ALT-803, Leukapheresis